Parc des Princes, 9/11/19, rugby, équipe du Stade Français [qui a battu l'équipe de Nantes] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56859

Claudin-19 mutations and clinical phenotype in Spanish patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis.

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis is an autosomal recessive tubular disorder characterized by excessive renal magnesium and calcium excretion and chronic kidney failure. This rare disease is caused by mutations in the CLDN16 and CLDN19 genes. These genes encode the tight junction proteins claudin-16 and claudin-19, respectively, which regulate the paracellular ion reabsorption in the kidney. Patients with mutations in the CLDN19 gene also present severe visual impairment. Our goals in this study were to examine the clinical characteristics of a large cohort of Spanish patients with this disorder and to identify the disease causing mutations. We included a total of 31 patients belonging to 27 unrelated families and studied renal and ocular manifestations. We then analyzed by direct DNA sequencing the coding regions of CLDN16 and CLDN19 genes in these patients. Bioinformatic tools were used to predict the consequences of mutations. Clinical evaluation showed ocular defects in 87% of patients, including mainly myopia, nystagmus and macular colobomata. Twenty two percent of patients underwent renal transplantation and impaired renal function was observed in another 61% of patients. Results of the genetic analysis revealed CLDN19 mutations in all patients confirming the clinical diagnosis. The majority of patients exhibited the previously described p.G20D mutation. Haplotype analysis using three microsatellite markers showed a founder effect for this recurrent mutation in our cohort. We also identified four new pathogenic mutations in CLDN19, p.G122R, p.I41T, p.G75C and p.G75S. A strategy based on microsequencing was designed to facilitate the genetic diagnosis of this disease. Our data indicate that patients with CLDN19 mutations have a high risk of progression to chronic renal disease.

2/6/19, remise du traité de paix aux Autrichiens [préliminaires du traité de Saint-Germain-en-Laye du 10 septembre, au château], MM. Clemenceau et Lloyd George : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54216

Requête de conclusions du 19 février 1704. A Nosseigneurs de parlement en la chambre de la Tournelle. (Pour Jean-Baptiste Lorieul, sieur de la Noue, accusé de banqueroute frauduleuse, contre les nommés Passerat, Briand et autres / [Signé : Claude Berroyer].)

[Factum. Lorieul de la Noue, Jean-Baptiste. 1704?]

1-11-19, [cimetière américain de] Suresnes, fête des morts : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56737

5-11-19, [M. Clemenceau] au pont de Kehl : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56809

Catalogue des livres portraits, gravures & instruments d'optique. Composant la Bibliothèque et le Cabinet De feu M. Grangeret de Lagrange conservateur-adjoint à la bibliothèque de l'Arsenal, membre du conseil de la Société asiatique, ancien correcteur pour les livres orientaux à l'Imprimerie impériale, etc. : La vente aura lieu ... Les Mardi 19, Mercredi 20, Jeudi 21 et Vendredi 22 Juillet 1859 / [expert] M. Auguste Aubry, Libraire

[Vente. Livres. 1859-07-19 - 1859-07-22]

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.

INTRODUCTION Monotherapy against HIV has undoubted theoretical advantages and has good scientific fundaments. However, it is still controversial and here we will analyze the efficacy and safety of MT with darunavir with ritonavir (DRV/r) on patients who have received this treatment in our hospitals. MATERIALS AND METHODS Observational retrospective study that includes patients from 10 Andalusian hospitals that have received DRV/r in MT and that have been followed over a minimum of 12 months. We carried out a statistical descriptive analysis based on the profile of patients who had been prescribed MT and the efficacy and safety that were observed, paying special attention to treatment failure and virological evolution. RESULTS DRV/r was prescribed to 604 patients, of which 41.1% had a CD4 nadir <200/mmc. 33.1% had chronic hepatitis caused by HCV, had received an average of five lines of previous treatment and had a history of treatment failure to analogues in 33%, to non-analogues 22 and protease inhibitors (PI) in 19.5%. 76.6% proceeded from a previous treatment with PI. The simplification was the main criteria for the instauration of MT in the 81.5% and the adverse effects in the 18.5%. We managed to maintain MT in 84% of cases, with only 4.8% of virological failure (VF) with viral load (VL) >200 c/mL and 3.6% additional losses due to VF with VL between 50 and 200 copies/mL. Thirty three genotypes were performed after failure without findings of resistance mutations to DRV/r or other IPs. Only 23.7% of patients presented some blips during the period of exposition to MT. Eighty seven percent of all determinations of VL had <50 copies/mL, and only 4.99% had >200 copies/mL. Although up to 14.9% registered at some point an AE, only 2.6% abandoned MT because of AE and 1.2% because of voluntary decision. Although the average of total and LDL cholesterol increases 10 mg/dL after 2 years of follow-up, so did HDL cholesterol in 3mg/dL and the values of triglycerides (-14 mg/dL) and GPT (-6 UI/mL) decreased. The average count of CD4 lymphocytes increased from 642 to 714/mm(3) at 24 weeks. CONCLUSIONS In a very broad series of patients obtained from clinical practice, data from clinical trials was confirmed: MT with DRV as a de-escalation strategy is very safe, it's associated to a negligible rate of adverse effects and maintains a good suppression of HIV replication. VF (with >50 or >200 copies/mL) is always under 10% and in any case without consequences.

Équipe [Royale] Union Saint-Gilloise, ([prix] Gondrand), Colombes, 9/11/19 : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56838

5-11-19, M. Clemenceau sort du fort de Kirchbach [avec M. Millerand] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56820

12/11/19, bateaux viviers à Paris : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56890

11/11/19, parc des Princes, rugby, équipe de l'U. S. Perpignanaise : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56881

5-11-19, M. Clemenceau [et M. Millerand] sur le pont du Rhin : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56816

5-11-19, M. Clemenceau [et M. Millerand] au pont de Kehl : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 56815